Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0043—Nose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/74—Synthetic polymeric materials
  • A61K31/765—Polymers containing oxygen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
  • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Definitions

• the present invention relates to a novel composition that is useful in the treatment of epistaxis (nosebleeding).
• the invention relates to a gel composition for the prophylaxis and treatment of epistaxis that can be easily administered to the nasal cavity and does not require removal after use.
• Epistaxis is very common. Although in most cases the symptoms are temporary and non-recurrent, some patients experience recurring and severe symptoms. The most common method of treating severe epistaxis is by cauterization of the bleeding vessel. When the source of bleeding cannot be seen, intranasal packing using cotton tampons or inflatable rubber balloons may be employed, but such methods cause inconvenience and discomfort for the patient.
• the cotton tampons typically have a width of 2 cm and a length of 40-100 cm. They are pressed into the nose to stop bleeding by applying pressure to the nasal mucosa and may stay in place for 1-4 days. Inflatable rubber balloons also act by applying pressure to the nasal mucosa, and may remain in place for 1 -2 days. Whether tampons or balloons are employed, either is painful when inserted, interferes with normal breathing and may lead to local infection. There is a need for treatments which do not have such disadvantages.
• WO 01/00218 describes a nasal spray formulation which includes Dead Sea salt in a concentration of about 0.5 to 5 g/1 of sterile aqueous solution, contains a buffer and is essentially free of noxious, organic impurities.
• the formulation is said to be for use in treating rhinitis, sinusitis, epistaxis and post-surgical irritation, but no trials relating to epistaxis are reported.
• the inventor has surprisingly discovered an improved composition for use as a nasal gel, which composition has all the advantageous properties of the aforementioned known placebo gel, whilst being more effective in the treatment of epistaxis.
• a gel composition comprising:
• the invention also provides a process for making the novel gel composition, comprising mixing water with the dry components (a), (b) and (c) above, in any desired order.
• the invention provides a method of treatment of epistaxis by prophylaxis or therapy, comprising inserting into a nasal cavity of a human or non- human animal an effective amount of a gel composition of the invention.
• the invention provides a gel composition of the invention for use in therapy, especially for use in the treatment of epistaxis.
• the invention provides the use of a gel composition of the invention in the treatment of epistaxis by prophylaxis or therapy.
• compositions are used for therapy in the form of gels, it is also possible to prepare compositions of the dry ingredients (a), (b) and (c) above, and then prepare gel compositions at a subsequent time, prior to use. Accordingly, in a still further aspect, the present invention provides a dry composition comprising: a) a carboxy polymethylene polymer; b) glycine; and c) a source of calcium ions.
• Carboxy polymethylene polymers are polymers of acrylic acid cross-linked with polyalkenyl ethers or divinyl glycol.
• Carbomers have the basic structural unit (CH 2 CH(COOH)J n - They are available in a range of grades from Noveon, Cleveland, Ohio, USA, under the brand name Carbopol. The grades differ according to the degree of cross-linking and manufacturing conditions.
• Raw carbomer polymers are white powders, but they are strongly hydrophilic, being capable of swelling in water up to 1000 times their original volume to form a gel.
• Carbomers are essentially biologically inert and have a long history of safe use in topical formulations of various kinds.
• the carbomer When introduced into the nasal cavity the carbomer has the effect of exerting a pressure on the mucosa and the bleeding vessel. In this way it acts like a tampon, which also exerts pressure against the mucosa and is used as treatment for epistaxis (see Background section above).
• the gel has the advantage over the tampon that there is usually no need to remove it, since it is transported by the mucociliary system through the nose backwards to the throat and is then swallowed within an hour or two after administration.
• Preferred carboxy polymethylene polymers for use in the present invention are those sold under the trade name Carbopol, available from Noveon.
• Carbopol 974P NF and Carbopol 97 IP NF are particularly preferred polymers.
• the amount of carboxy polymethylene polymer used will vary depending on the identity of the polymer(s).
• the carboxy polymethylene polymer typically constitutes from 5 to 50% by weight of the total dry ingredients, preferably from 10 to 35 wt.%, more preferably from 15 to 30 wt.%, most preferably about 20 wt.%.
• Gel compositions of the invention can be formed using a concentration of carboxy polymethylene polymer which is typically from 10 to 100 g dry weight per litre of gel, preferably from 20 to 50 g/1, more preferably from 30 to 40 g/1, most preferably about 35 g/1.
• the second component in the gel is the amino acid glycine (aminoacetic acid). It is not a so-called "essential amino acid", and can be produced by the human body itself being the simplest of all the 20 amino acids. Glycine is involved in a great variety of metabolic reactions and takes part in the formation of proteins in the human body.
• glycine confers a hyperosmotic activity on the gel. Water is drawn from the nasal mucosa, which means that the mucosa becomes decongested and shrinks, the blood-flow into the vessels decreases and the bleeding may be arrested. As glycine is a building-block for human cells it may also play a role in the restoration of the nasal mucosa and blood vessel wall.
• Glycine is a widely commercially available material.
• glycine typically constitutes from 30 to 90% by weight of the total ingredients, preferably from 50 to 80 wt.%, more preferably around 70 wt.%.
• the concentration of glycine is typically from 50 to 200 g dry weight per litre of gel, preferably from 80 to 150 g/1, more preferably from 110 to 120 g/1, most preferably about 1 17 g/1.
• the third essential component is a source of calcium ions (Ca" 4 ).
• Calcium ions are implicated in biological coagulation processes. In the last steps of blood coagulation thrombin transforms the protein fibrinogen (molecular weight 340,000) to soluble fibrin. Finally, the soluble fibrin can be converted to an insoluble fibrin, which can withstand mechanical forces much more effectively, as a result of which a rebleeding may be prevented. Without wishing to be bound by any theory, it is believed that the conversion of fibrin to an insoluble form proceeds more rapidly in the presence of calcium ions, the absorption of which may be enhanced as a result of the nasal mucosa being very thin.
• the calcium ions may be present in any convenient form, but are preferably in the form of a soluble salt, for example the chloride, or another salt, e.g. acetate, phosphate, carbonate or gluconate. Calcium chloride is most preferred.
• the total amount of calcium ions is typically from 0.005 to 0.1% by weight of the total dry ingredients, preferably from 0.01 to 0.05 wt.% , more preferably from
• the concentration of calcium ions is typically from 10 to 200 mg per litre of gel, preferably from 20 to 100 mg/1, more preferably from 40 to 70 mg/1, most preferably about 58 mg/1.
• Water is employed when formulating the compositions in the form of a gel, e.g. prior to administration to the patient.
• the amount of water used is that required to form a gel of the appropriate viscosity when mixed with the other components. This will vary depending on the identity of the carboxy polymethylene polymer(s) used.
• water comprises 750-950 g per kg of gel, preferably 800-900 g/kg, more preferably around 850 g/kg.
• pH adjusting agents ascids, alkalis, buffers
• preservatives e.g. methargen, propagin
• antioxidants e.g. methargen, propagin
• compositions of the invention as gels for clinical use, the following steps are carried out.
• a source of calcium ions e.g. calcium chloride
• a suitable amount of acid, alkali or buffer material may be added to the water in order to ensure that the final gel has a suitable pH, e.g. in the range 6.5-7.5.
• Glycine is then added with stirring until dissolution is complete.
• Carboxy polymethylene polymer is then added slowly and carefully (e.g. by gradually sprinkling the powder into the aqueous liquid) with stirring. Stirring is continued until all the polymer has dissolved.
• the pH of the gel may be checked to ensure that it is within the required range of 6.5-7.5.
• the dry ingredients may firstly be mixed together, and then water is added in a suitable quantity to form a gel of appropriate viscosity.
• the skilled person can establish, e.g. by trial and error, the amount of water that is suitable for forming a gel of appropriate viscosity.
• the preparation of the gel may be carried out at any suitable temperature. However, preparation at room temperature is most convenient.
• compositions are used in the form of gels.
• the patient Prior to use, the patient should be asked to blow his nose.
• the internal nasal surfaces should then be gently cleansed, in order to maximise contact between the gel and the nasal mucosa.
• the gel should be inserted in the nostril(s) that are subject to bleeding, for example using a prefilled syringe.
• the entire nasal cavity should be filled. (This can be done by discontinuing the administration of the gel when the patient indicates that the gel is beginning to run down the back of the nasal cavity into his throat.) However, it may not be necessary to fill the entire nasal cavity if the bleeding has clearly ceased before filling is complete. A small piece of cotton or other suitable plug may then be placed in the patient's nostril. The patient should refrain from blowing his nose for a sufficient time to allow the gel to be effective, for example 30 minutes.
• EXAMPLE EXAMPLE

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Otolaryngology (AREA)
• Inorganic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pulmonology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (2)

Family

ID=37909023

Family Applications (1)

Country Status (19)

Cited By (1)

Families Citing this family (1)

Family Cites Families (18)

• 2007
  • 2007-02-21 GB GB0703377A patent/GB2447012B/en not_active Expired - Fee Related
• 2008
  • 2008-02-21 DK DK08709491.8T patent/DK2117502T3/en active
  • 2008-02-21 KR KR1020097019543A patent/KR20090130001A/ko not_active Ceased
  • 2008-02-21 PL PL08709491T patent/PL2117502T3/pl unknown
  • 2008-02-21 CA CA2678706A patent/CA2678706C/en active Active
  • 2008-02-21 BR BRPI0807732A patent/BRPI0807732B8/pt not_active IP Right Cessation
  • 2008-02-21 WO PCT/GB2008/000608 patent/WO2008102150A2/en not_active Ceased
  • 2008-02-21 HR HRP20161626TT patent/HRP20161626T1/hr unknown
  • 2008-02-21 PT PT87094918T patent/PT2117502T/pt unknown
  • 2008-02-21 RU RU2009134086/15A patent/RU2473327C2/ru not_active IP Right Cessation
  • 2008-02-21 EP EP08709491.8A patent/EP2117502B1/en active Active
  • 2008-02-21 CN CN200880005428.8A patent/CN101677940B/zh not_active Expired - Fee Related
  • 2008-02-21 ZA ZA200905519A patent/ZA200905519B/xx unknown
  • 2008-02-21 ES ES08709491.8T patent/ES2606947T3/es active Active
  • 2008-02-21 US US12/525,975 patent/US9138406B2/en active Active
  • 2008-02-21 HU HUE08709491A patent/HUE031199T2/en unknown
  • 2008-02-21 AU AU2008217608A patent/AU2008217608B2/en not_active Ceased
  • 2008-02-21 JP JP2009550758A patent/JP2010519285A/ja active Pending
• 2009
  • 2009-08-06 IL IL200277A patent/IL200277A0/en unknown

Also Published As

Similar Documents

Legal Events